‐
Glenmark is the
first company in India to launch Thiazolidinedione Lobeglitazone (0.5 mg).
‐
This anti-diabetic
medication will be marketed under brand name LOBG.
‐
With this launch,
the company aims to improve glycemic levels in uncontrolled diabetics and create
a new pathway to treat insulin resistance in India.
‐
Glenmark’s LOBG is
priced at approximately INR 10 per tablet, per day.
Glenmark Pharmaceuticals Limited (Glenmark), an innovation-driven
global pharmaceutical company, became the first to launch Thiazolidinedione
Lobeglitazone (Lobeglitazone) in India for the treatment of type 2 diabetes in
adults. Marketed under the brand name LOBG; it contains Lobeglitazone (0.5 mg)
and tobe taken once daily under prescription to improve glycemic control in
adult diabetic patients. Indians have a high prevalence of insulin resistance and
that makes LOBG an appealing treatment option in managing uncontrolled Type 2 diabetes
among insulin-resistant diabetic patients.
Glenmark earlier received approval
from the Indian drug regulator, Drug Controller General of India, for
manufacturing and marketing Lobeglitazone based on a randomized, double-blind
Phase 3 clinical trial conducted on adult Type 2 diabetic patients, aged 18
years and older.The results of this trial have shown a faster and improved glycemic
control with Lobeglitazone.
On the occasion of the launch, Alok Malik, EVP&Business Head - India Formulations,
Glenmark Pharmaceuticals, said,“As
per the International Diabetes Federation, diabetes affects 74 million adults
in India, of which, around 40% of them seem to be insulin-resistant. As a
leading solutions provider in India for the treatment of diabetes, we are proud
to introduce LOBG;an innovative and affordable drug, which will help in
tackling insulin resistance among adult patients suffering from uncontrolled
Type 2 diabetes in the country.”
Glenmark and Diabetes in India
Glenmark has a strong legacy of
bringing new and effective treatment options fordiabetic patients.In 2015, Glenmark
revolutionized diabetes treatment in India by being the first to launch the
DPP4 inhibitor –Teneligliptin, followed by a fixed dose combination of
Teneligliptin + Metformin. In continuation towards its legacy, Glenmark
launched Remogliflozin, a novel SGLT-2 inhibitor in 2019 after its first global
approval in India and subsequently launched its combinations with metformin and
Vildagliptin.
According to IQVIA™ sales data for the 12‐month period ending Aug.
2022, the market for oral anti-diabetic drugs in India is estimated to be INR
11,725 cr. with an annual growth of 7% against the corresponding period last
year (MAT Aug 2021). As per the International Diabetes Federation (IDF), the
prevalence of diabetes in India is expected to increase to 125 million by 2045[i].
Out of these, 77% of patients have uncontrolled diabetes. Moreover every four
out of ten diabetic patients seem to have insulin resistance in India[ii].
